Retinal organoids derived from iPSCs with RPGR gene mutation from retinitis pigmentosa patients not only recapitulated the pathogenesis but also provided proof-of-concept evidence for targeted gene therapy by correction of RPGR mutations [19]. The gene discussed is RPGR; the disease is retinitis pigmentosa.